The Armchair Analyst

The Armchair Analyst

5-minute daily updates on the ASX life-sciences sector.

Recent Articles

The Economics of Psychedelic Therapy

The Economics of Psychedelic Therapy

Apr 21, 2026

•

7 min read

Trump Greenlights Psychedelics in the US for PTSD

Trump Greenlights Psychedelics in the US for PTSD

Apr 20, 2026

•

2 min read

My Second Armchair Pick: Emyria (ASX: EMD)

My Second Armchair Pick: Emyria (ASX: EMD)

Apr 20, 2026

•

11 min read

A Beacon of Australian Biotech: The Telix (ASX: TLX) Story

A Beacon of Australian Biotech: The Telix (ASX: TLX) Story

Apr 17, 2026

•

9 min read

Riding the Peptidal Wave: Biotech Bounce Back

Riding the Peptidal Wave: Biotech Bounce Back

Apr 16, 2026

•

3 min read

Betadine II: Lost in Translation. Inside Firebrick Pharma (ASX: FRE) Story

Betadine II: Lost in Translation. Inside Firebrick Pharma (ASX: FRE) Story

Apr 15, 2026

•

15 min read

When Shares Become the Vote: The 249D-ilemma

When Shares Become the Vote: The 249D-ilemma

Apr 14, 2026

•

7 min read

Telix lights up the deal docket for the ASX biotech sector

Telix lights up the deal docket for the ASX biotech sector

Apr 13, 2026

•

8 min read

While everyone is selling. Big Pharma is buying.

While everyone is selling. Big Pharma is buying.

Apr 10, 2026

•

6 min read

Market’s Rocking: A Green Day

Market’s Rocking: A Green Day

Apr 9, 2026

•

6 min read

Second Mover Advantage: The Neuroscientific Biopharmaceutical (ASX: NSB) Story

Second Mover Advantage: The Neuroscientific Biopharmaceutical (ASX: NSB) Story

Apr 8, 2026

•

15 min read

A 20-Year Rollercoaster: The Mesoblast (ASX: MSB) Story

A 20-Year Rollercoaster: The Mesoblast (ASX: MSB) Story

Apr 7, 2026

•

21 min read

...